News | August 12, 2024
Lupin Q1 FY25 profit up 77% at Rs. 801 Cr
Revenue up 16.3% to Rs 5,600 crore versus Rs 4,814 crore
Revenue up 16.3% to Rs 5,600 crore versus Rs 4,814 crore
Being the first approved applicant, Lupin is eligible for 180 days of CGT exclusivity
The successful completion of the global Phase 3 trials paves the way to obtain marketing approval in the U.S. and EU
This product will be manufactured at Lupin’s Nagpur facility in India and will be supplied to low and middle-income countries
Cyclosporine Ophthalmic Nanoemulsion is a preservative-free Nanoemulsion that has been approved in South Korea, Peru and several countries in the Middle East for treatment of dry eye syndrome
Doxorubicin Hydrochloride Liposome Injection (RLD Doxil) had estimated annual sales of USD 42 million in the U.S. (IQVIA MAT May 2024)
Lupin can receive a potential total consideration of up to USD 84 million based on future contingent milestones
The facility is a part of Lupin Manufacturing Solutions
This product will be manufactured at Lupin’s Pithampur facility in India
The facility was inspected from May 7 to May 17, 2024
Subscribe To Our Newsletter & Stay Updated
